FPPRGD2 F-18

Investigational

Details

Stereochemistry	EPIMERIC
Molecular Formula	C70H105FN20O23
Molecular Weight	1612.7038
Optical Activity	UNSPECIFIED
Defined Stereocenters	9 / 10
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CC([18F])C(=O)NCCOCCOCCOCC(=O)N[C@@H](CCC(=O)NCCCC[C@@H]1NC(=O)[C@@H](CC2=CC=C(O)C=C2)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CCCNC(N)=N)NC1=O)C(=O)NCCCC[C@@H]3NC(=O)[C@@H](CC4=CC=C(O)C=C4)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CCCNC(N)=N)NC3=O

InChI

InChIKey=YAOQNDCEKABEDO-RTOYRMACSA-N

InChI=1S/C70H105FN20O23/c1-39(71)59(102)78-26-27-112-28-29-113-30-31-114-38-56(97)83-48(60(103)77-23-5-3-9-47-64(107)87-45(11-7-25-80-70(74)75)62(105)82-37-55(96)85-52(35-58(100)101)68(111)91-50(66(109)89-47)33-41-14-18-43(93)19-15-41)20-21-53(94)76-22-4-2-8-46-63(106)86-44(10-6-24-79-69(72)73)61(104)81-36-54(95)84-51(34-57(98)99)67(110)90-49(65(108)88-46)32-40-12-16-42(92)17-13-40/h12-19,39,44-52,92-93H,2-11,20-38H2,1H3,(H,76,94)(H,77,103)(H,78,102)(H,81,104)(H,82,105)(H,83,97)(H,84,95)(H,85,96)(H,86,106)(H,87,107)(H,88,108)(H,89,109)(H,90,110)(H,91,111)(H,98,99)(H,100,101)(H4,72,73,79)(H4,74,75,80)/t39?,44-,45-,46-,47-,48-,49+,50+,51-,52-/m0/s1/i71-1

HIDE SMILES / InChI

Molecular Formula	C70H105FN20O23
Molecular Weight	1612.7038
Charge	0
Count

Stereochemistry	EPIMERIC
Additional Stereochemistry	No
Defined Stereocenters	9 / 10
E/Z Centers	4
Optical Activity	UNSPECIFIED

Approval Year

Substance Class	Chemical Created by `admin` on `Sat Dec 16 11:29:01 UTC 2023` Edited by `admin` on `Sat Dec 16 11:29:01 UTC 2023`
Record UNII	E8XU52J025
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

FPPRGD2 F-18

Common Name

English

(18F)FPPRGD2

Common Name

English

CYCLO(L-ARGINYLGLYCYL-L-.ALPHA.-ASPARTYL-D-PHENYLALANYL-L-LYSYL), 5,5'-(N-(14-(FLUORO-18F)-1,13-DIOXO-3,6,9-TRIOXA-12-AZAPENTADEC-1-YL)-L-GLUTAMOYL)BIS-

Systematic Name

English

5,5'-(N-(14-(FLUORO-18F)-1,13-DIOXO-3,6,9-TRIOXA-12-AZAPENTADEC-1-YL)-L-GLUTAMOYL)BIS(CYCLO(L-ARGINYLGLYCYL-L-.ALPHA.-ASPARTYL-D-PHENYLALANYL-L-LYSYL))

Systematic Name

English

2-((2S,5R,8S,11S)-5-BENZYL-8-(4-(((4S)-5-(4-((2S,5S,11S,14R)-14-BENZYL-11-(CARBOXYMETHYL)-5-(3-GUANIDINOPROPYL)-3,6,9,12,15-PENTAOXO-1,4,7,10,13-PENTAZACYCLOPENTADEC-2-YL)BUTYLAMINO)-4-((2-(2-(2-(2-(2-FLUORANYLPROPANOYLAMINO)ETHOXY)ETHOXY)ETHOXY)ACETYL)A

Systematic Name

English

Code System Code Type Description

FDA UNII

E8XU52J025

Created by admin on Sat Dec 16 11:29:01 UTC 2023 , Edited by admin on Sat Dec 16 11:29:01 UTC 2023

PRIMARY

CAS

1346416-53-2

Created by admin on Sat Dec 16 11:29:01 UTC 2023 , Edited by admin on Sat Dec 16 11:29:01 UTC 2023

PRIMARY

PUBCHEM

134823891

Created by admin on Sat Dec 16 11:29:01 UTC 2023 , Edited by admin on Sat Dec 16 11:29:01 UTC 2023

PRIMARY

Related Record Type Details


					E8XU52J025

FPPRGD2 F-18

ACTIVE MOIETY

Comments:

The administration of 18F-FPPRGD2 was well tolerated, with no marked effects on vital signs, ECG readings, or laboratory values. The tracer showed the same pattern of biodistribution in all volunteers: primary clearance through the kidneys (0.360 rem/mCi +/- 0.185 (0.098 mSv/MBq +/- 0.050)) and bladder (0.862 rem/mCi +/- 0.436 (0.233 mSv/MBq +/- 0.118), voiding model) and uptake in the spleen (0.250 rem/mCi +/- 0.168 (0.068 mSv/MBq +/- 0.046)) and large intestine (0.529 rem/mCi +/- 0.236 (0.143 mSv/MBq +/- 0.064)). The mean effective dose of 18F-FPPRGD2 was 0.1462 rem/mCi +/- 0.0669 (0.0396 mSv/MBq +/- 0.0181). With an injected dose of 10 mCi (370 MBq) and a 1-hour voiding interval, a patient would be exposed to an effective radiation dose of 1.5 rem (15 mSv). Above the diaphragm, there was minimal uptake in the brain ventricles, salivary glands, and thyroid gland. Time-activity curves showed rapid clearance from the vasculature, with a mean 26% +/- 17 of the tracer remaining in the circulation at 30 minutes and most of the activity occurring in the plasma relative to cells (mean whole bloodplasma ratio, 0.799 +/- 0.096).


					E8XU52J025

FPPRGD2 F-18

ACTIVE MOIETY

Comments:

Official Title: Phase I/II 18F FPPRGD2 PET/CT or PET/MRI Imaging of .ALPHA.v.BETA.3 Integrins Expression as a Biomarker of Angiogenesis Purpose: The purpose of the study is to conduct research of a new PET radiopharmaceutical in cancer patients. We will assess the uptake of this novel radiopharmaceutical in subjects with breast cancer, lung cancer, glioblastoma multiforme (GBM) and other cancers requiring antiangiogenesis treatment.